WDBMD acquires DZS Clinical Services, deal to leverage complementary CRO services, says CEO

By Maggie Lynch contact

- Last updated on GMT

Image: Getty/AndreyPopov)
Image: Getty/AndreyPopov)

Related tags: Contract research organization, CRO, acquistion, Clinical development, Biotech companies

DZS Clinical Services has been acquired by the global CRO WDMD in a deal that will expand its service offerings globally with the addition of coverage in Europe and Japan.

WDB Holdings’ subsidiary and contract research organization (CRO) WDB Medical Data (WDBMD) acquired DZS Clinical Services (DZS) and all its resources and processes.

Greg Ambra, president of DZS, told us the acquisition will leverage “synergies and complementary CRO services”​ between WDBND and DZS.

DZS provides clinical development and data analytic services, and the acquisition will “bolster its full-service CRO capabilities” ​while providing more coverage in Europe and Japan, according to Ambra.

The acquisition also will strengthen WDBMD’s capabilities and presence in the US. Ambra added, “WDBMD supplements DZS Clinical Services offering with pharmacovigilance and regulatory affairs services, in addition to access to a medical call center.”

The leadership team at DZS will remain intact and the company’s facilities in New Jersey will remain open with an additional office to be established in Sunnyvale, California.

Financial details were not disclosed. 

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more